Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) (TNFRSF12A)

Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A), also known as Fn14, is a type I transmembrane protein that serves as the sole high-affinity receptor for the cytokine TWEAK (TNF-like weak inducer of apoptosis) [UniProt Q9NP84]. Under normal physiological conditions, TNFRSF12A expression is minimal in most healthy tissues but is rapidly and dramatically upregulated following tissue injury, chronic inflammation, or malignant transformation [Winkles, 2008]. Upon binding to TWEAK, the receptor recruits TNFR-associated factors (TRAFs) to activate multiple downstream signaling pathways, including the canonical and non-canonical NF-kappaB and MAPK pathways, which regulate cell proliferation, migration, and survival [Burkly, 2014]. In disease contexts, the TWEAK/Fn14 axis is heavily implicated in promoting tumor growth, metastasis, and angiogenesis, as well as driving chronic inflammatory conditions such as lupus nephritis and rheumatoid arthritis [Xia et al., 2015]. Therapeutic strategies targeting this receptor include antagonistic monoclonal antibodies designed to block pro-inflammatory signaling and agonistic or toxin-conjugated antibodies intended to selectively eliminate Fn14-overexpressing cancer cells [ClinicalTrials.gov]. While several candidates like Enavatuzumab and RG7212 have entered clinical trials, challenges remain regarding their efficacy as monotherapies and the management of potential side effects like hepatotoxicity [Ciprotti et al., 2015].

Other names

Fn14TWEAK receptorTWEAKRCD266Fibroblast growth factor-inducible 14

Therapeutic agents targeting TNFRSF12A primarily function as monoclonal antibodies that either antagonize the receptor by blocking its interaction with the ligand TWEAK, thereby inhibiting pro-inflammatory and pro-survival signaling, or act as agonists/ADCC-inducers to selectively eliminate Fn14-overexpressing malignant cells.